Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

Br J Cancer. 2018 May;118(9):1176-1178. doi: 10.1038/s41416-018-0061-6. Epub 2018 Mar 26.


Background: In the phase 3 METEOR trial (NCT01865747), cabozantinib significantly improved progression-free survival, overall survival, and objective response rate compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy. A statistically significant improvement in overall survival was observed at a second interim analysis with 320 recorded deaths.

Methods: 658 patients with advanced RCC who had received at least one prior VEGFR tyrosine kinase inhibitor were randomised 1:1 to cabozantinib (60 mg daily) or everolimus (10 mg daily). Survival follow-up continued to reach the 408 deaths that were pre-specified for the final analysis.

Results: With 430 deaths (198 for cabozantinib and 232 for everolimus), median overall survival was 21.4 months with cabozantinib and 17.1 months with everolimus (HR 0.70, 95% CI 0.58-0.85; P = 0.0002). Safety profiles of cabozantinib and everolimus were consistent with those reported previously.

Conclusions: Cabozantinib significantly improved overall survival compared with everolimus in previously treated patients with advanced RCC with consistent results after long-term follow-up.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use
  • Anilides / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / mortality*
  • Carcinoma, Renal Cell / pathology
  • Disease Progression
  • Everolimus / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / mortality*
  • Kidney Neoplasms / pathology
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridines / therapeutic use*
  • Survival Analysis


  • Angiogenesis Inhibitors
  • Anilides
  • Protein Kinase Inhibitors
  • Pyridines
  • cabozantinib
  • Everolimus